|
|
|||
|
|||
|
|
|||
|
food allergy cure |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
food allergy cure DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide food allergy cure. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water food allergy cure. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone food allergy cure. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration food allergy cure. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide food allergy cure.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans food allergy cure. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs food allergy cure. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness food allergy cure. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges food allergy cure. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma food allergy cure. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma food allergy cure. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge food allergy cure. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma food allergy cure. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma food allergy cure. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg food allergy cure. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data food allergy cure. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% food allergy cure. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below food allergy cure. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed food allergy cure. Elderly: The apparent oral clearance of zafirlukast decreases with age food allergy cure. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients food allergy cure. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults food allergy cure. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects food allergy cure. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects food allergy cure. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ffood allergy cure foood allergy cure foood allergy cure foodd allergy cure food allergy cure food aallergy cure food alllergy cure food alllergy cure food alleergy cure food allerrgy cure food allerggy cure food allergyy cure food allergy cure food allergy ccure food allergy cuure food allergy curre food allergy curee ood allergy cure fod allergy cure fod allergy cure foo allergy cure foodallergy cure food llergy cure food alergy cure food alergy cure food allrgy cure food allegy cure food allery cure food allerg cure food allergycure food allergy ure food allergy cre food allergy cue food allergy cur f ood allergy cure fo od allergy cure foo d allergy cure food allergy cure food allergy cure food a llergy cure food al lergy cure food all ergy cure food alle rgy cure food aller gy cure food allerg y cure food allergy cure food allergy cure food allergy c ure food allergy cu re food allergy cur e food allergy cure ofod allergy cure food allergy cure fodo allergy cure foo dallergy cure fooda llergy cure food lalergy cure food allergy cure food alelrgy cure food allregy cure food allegry cure food alleryg cure food allerg ycure food allergyc ure food allergy ucre food allergy crue food allergy cuer afood allergy cure thefood allergy cure food allergy cure | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
